The Food and Drug Administration (FDA) of the United States has approved RINVOQ for the purpose of treating the adults suffering with the active Ankylosing spondylitis (AS), who have been having an inadequate response or the intolerance to more tumor necrosis factor (TNF) blockers.
Thomas Hudson, senior vice president and MD, research and development at AbbVie said, the disease Ankylosing Spondylitis is mostly affecting the younger adults and over the time, it can possibly result in lasting the structural damage, which can possibly take an emotional toll on a life of a patient.
The approval of the US FDA has been supported by the efficacy and safety data from the Phase 3 SELET-AXIS 2 clinical trial along with evaluating the RINVOQ in the patients, who is having an inadequate response or having intolerance to one or two biologic ant-rheumatic drugs.
Atul Deodhar, MD, Professor of medicine and medical director of Rheumatology Clinic for the Division of Arthritis and Rheumatic Diseases at the Oregon Health and Science University said, most of the patients with the ankylosing spondylitis does not achieve the disease control along with the current therapies and additional treatments have been needed for helping them in relieving the symptoms and signs of this disease.
He also said that, with approval of US FDA, the patients who does not respond to a TNF inhibitor, who is having an additional oral treatment option in the partnership with the rheumatologist for the purpose of helping them to take control of this disease.